← All diseases
Liver, kidneys and digestion
Fatty liver disease (MASH/NASH), advanced
Do you want to receive a message when there is new research about Liver Fat (MASH/NASH), advanced? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, a single sentence appears above each publication explaining what was studied — and you'll be notified as soon as new research on Liver Steatosis (MASH/NASH), Advanced is available. View what Premium costs.
Publications and studies (2544)
- Impact of Obeticholic Acid Therapy on Insulin Resistance and Metabolic Parameters in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). (2026/08/06) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Hepatotropic Nanomedicine and Targeted Nanocarriers for Liver Diseases and Hepatocellular Carcinoma. (2026/08/05) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Acromegaly and Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical and Therapeutic Implications. (2026/08/05) ♡
- Metabolic Dysfunction-Associated Steatohepatitis Comorbidity Burden and Overall, Waiting-List, and Post-Liver Transplant Mortality. (2026/08/05) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Intrahepatic Klebsiella pneumoniae is associated with host cellular dysfunction in metabolic dysfunction-associated steatohepatitis. (2026/08/04) ♡
- S100A11 regulates hepatic cholesterol metabolism and promotes steatohepatitis via non-canonical SREBP2 signaling. (2026/08/04) ♡
- Torsins organize CLCC1 assembly to safeguard ER bilayer and lipid homeostasis. (2026/08/04) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Ginkgo biloba L. in preventing cardiovascular disease: pharmacological effects, mechanism of action, and therapeutic potential. (2026/08/04) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Rapamycin-induced fatty liver in mice is attenuated by chloroquine co-treatment in an ERRα-dependent manner. (2026/08/03) ♡
- Liver Endothelia Orchestrate MASH-Associated Macrophage Zonation Through FSTL1-ITGA4 Axis. (2026/08/03) ♡
- Reproducibility of Biomarkers in MASLD: A Benchmark for Clinically Meaningful Change in Serially Measured Non-Invasive Tests. (2026/08/03) ♡
- Golgi Protein 73 and Laminin-γ2 Monomer-Based Score for the Diagnosis of Advanced Liver Fibrosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. (2026/08/02) ♡
- Outcomes of Metabolic and Bariatric Surgery Among Adolescents and Young Adults in Southern Louisiana. (2026/08/01) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Environmental Endocrine-Disrupting Chemicals and Metabolic Dysfunction-Associated Steatotic Liver Disease. (2026/08/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Drug Development for MASH-Related Compensated Cirrhosis: Past, Present and Future. (2026/08/01) ♡
- Glucosamine Promotes Autophagy and Attenuates Hepatic Steatosis Via O-GlcNAcylation-Mediated Mechanisms. (2026/08/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Dual Roles of Free Fatty Acids in Gout Pathogenesis: Inflammatory Drivers and Metabolic Mediators. (2026/08/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice. (2026/08/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Is MASLD an independent risk factor for micro- and macrovascular complications of diabetes? A critical reappraisal and future directions. (2026/08/01) ♡
- Jiuwei Xiaozhi Decoction Alleviates High-Fat Diet-Induced MASLD by Suppressing Hepatic SREBP2-Driven Cholesterogenesis and Restoring PPARα-Mediated Fatty Acid Oxidation. (2026/08/01) ♡
- Neutrophils Promote Metabolic Dysfunction-Associated Steatotic Liver Disease Through Extracellular Vesicle-mediated Lipid Transfer. (2026/08/01) ♡
- Multi-Omics Analysis Identifies Tryptophan Metabolism and Glycolysis as Potential Pathways Involved in the Protective Effects of Tormentic Acid Against Metabolic Associated Fatty Liver Disease. (2026/08/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. DGAT2 inhibition in MASH: histologic promise and lipid paradox. (2026/08/01) ♡
- Development and Validation of a Symptom-Based Patient-Reported Outcome Measure for MASH: The CLDQ-MASH Symptom Questionnaire (CLDQ-MASH-SQ). (2026/07/31) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Mechanisms and therapeutic potential of AMPK signaling pathway in the regulation of lipid metabolism. (2026/07/31) ♡
- Association between non-HDL-C and nonalcoholic fatty liver disease (NAFLD) in adults aged 20 years and older: A population-based study in western China. (2026/07/31) ♡
- Characterization of Post-translational Modification in Metabolic Dysfunction-Associated Steatohepatitis: Acetylation, Lactylation, and Phosphorylation. (2026/07/31) ♡
- Associations of Helicobacter pylori infection with NAFLD, MAFLD, MASLD, and Chinese MAFLD. (2026/07/31) ♡
- Endogenous phosphatidylcholine 16:0/20:4 increases to promote liver regeneration in hepatectomy. (2026/07/31) ♡
- Progressive impairment of bioengineered skeletal muscles by MASLD-derived factors: a platform to model liver-induced muscle wasting. (2026/07/30) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Hepatic T-cell dysfunction in chronic liver disease and hepatocellular carcinoma: a spatial systems immunology framework for precision immunotherapy. (2026/07/30) ♡
- Tofogliflozin alters amino acid metabolism in gut microbiota linked to hepatic transcriptomic signatures in MASLD. (2026/07/30) ♡
- The promise of deep urine proteomics for diagnosis of cancer, neurologic, and metabolic diseases. (2026/07/30) ♡
- Curdlan alleviates non-alcoholic fatty liver disease by enriching butyrate-producing gut microbiota-liver axis. (2026/07/30) ♡
- Hepatic steatosis affects the outcome of anti-tuberculosis treatment in pulmonary tuberculosis patients. (2026/07/30) ♡
- Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset. (2026/07/29) ♡
- Unique nonclinical safety profile of PF-06835919, a ketohexokinase inhibitor, highlights a species-dependent mechanism. (2026/07/28) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. GLP-1 receptor agonists at the crossroads of diabetes, hepatic steatosis, and hepatocellular carcinoma. (2026/07/28) ♡
- Joint effects of social determinants of health on NAFLD mortality: the mediating role of phenotypic age acceleration. (2026/07/28) ♡
- Wedelolactone targets SORBS1 to regulate glycolipid metabolism and suppress inflammation, thereby alleviating diet-induced MASH via multiple pathways. (2026/07/28) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Mineralocorticoid Receptor Antagonists for Liver Fibrosis: Potential Mechanisms and Research Progress. (2026/07/28) ♡
- Curculigoside A alleviates metabolic dysfunction-associated steatohepatitis by targeting Rab30 to improve lipid homeostasis. (2026/07/28) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Intestinal lipase inhibition uncouples diet-induced obesity from MASH by remodeling the hepatic lipidome in mice. (2026/07/27) ♡
- The risk of cardiovascular events in metabolic dysfunction-associated steatotic liver disease according to fibrosis stage and diabetes status: A cohort study. (2026/07/27) ♡
- Identification of Core Pathways in Perfluorooctane Sulfonamide-Induced Liver Injury Using a Network Toxicology Approach. (2026/07/24) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Beyond the gut-dietary fiber mediated interorgan crosstalk and systemic health: Mechanistic insights and human evidence. (2026/07/24) ♡
- Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study. (2026/07/24) ♡
- Pan-Peroxisome Proliferator-Activated Receptor Agonist IVA337 Alleviates Secondary Lymphedema via Inhibiting TGFβ/SMAD2/3 Signaling Pathway. (2026/07/24) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Exercise and cold exposure as dual physiological stressors in MASLD: AMPK-mediated metabolic adaptation and interorgan crosstalk. (2026/07/24) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Combined Dyslipidemia in Children and Adolescents. (2026/07/23) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.